ACE inhibitory casein peptide lowers blood pressure and reshapes gut microbiota in a randomized double blind placebo controlled trial - Li, Kexin; Jiang, Peng; Li, Shuangqi; Sun, Jin; Qi, Ce (Scientific reports, 2025)
Keywords: 692/699/75/243; 692/700/2814; 692/700/565/2072; Adult; Amino acids; Angiotensin; Angiotensin II; Angiotensin-converting enzyme inhibitors; Angiotensin-Converting Enzyme Inhibitors - pharmacology; Angiotensin-Converting Enzyme Inhibitors - therapeutic use; Antihypertensive Agents - pharmacology; Antihypertensive Agents - therapeutic use; Antihypertensive effect; Antihypertensives; Arginine; Blood pressure; Blood Pressure - drug effects; Casein; Casein hydrolysate; Caseins - chemistry; Caseins - pharmacology; Caseins - therapeutic use; Clinical trials; Double-Blind Method; Double-blind randomized placebo-controlled clinical study; Enzyme inhibitors; Enzymes; Female; Gastrointestinal Microbiome - drug effects; Gut microbiota; Humanities and Social Sciences; Humans; Hypertension; Hypertension - drug therapy; Inflammation; Intestinal microflora; Male; Microbiota; Middle Aged; multidisciplinary; Peptides; Peptidyl-dipeptidase A; Placebos; Science; Science (multidisciplinary); Valine; Hypertension; Microbiota; Casein hydrolysate; Double-blind randomized placebo-controlled clinical study; Antihypertensive effect